DrugDashboards

Sumatriptan Succinate

Sumatriptan Succinate · SUMATRIPTAN SUCCINATE 6 mg/.5mL · Injection · Subcutaneous · Fresenius Kabi USA, LLC

NDC 63323-0273-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / .5 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

11 companies supply this market — deep enough that no single failure threatens the supply. The price has fallen 86% in a year, to $15.00 per mL — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want. Historically, drugs in this position went on to a new shortage within 90 days about 0.5% of the time — roughly 3× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$15.00per MLinvoice-surveyed acquisition cost · Jul 22, 2026
  • Part D plans paid (avg)$169.56per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal contracts pay (FSS)$17.93per package of 0.5MLFresenius Kabi, LLC · May 15, 2025

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 55111-0693-12) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$86.78per unit
middle half $57.14$119.45 · 5,294 plans · Apr 1, 2026
Est. net of rebates
≈ $86.78
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
96%of plans cover it
tier 4 · prior auth 0% · step therapy 0% · qty limit 96%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$50.00$100.00$150.00Apr 2014Sep 2026$15.00
11 price points · per ML · held since Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$49.00
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$35,997
717 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for sumatriptan succinate (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $24.59 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA079242
TE code
AP
Approval date
Mar 2, 2009
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Sumatriptan Succinate (Injection)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals Inc.SUMATRIPTAN SUCCINATE 4 mg/.5mLJul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals Inc.SUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedSUMATRIPTAN SUCCINATE 4 mg/.5mLJul 15, 2026Sep 2, 2026
Alembic Pharmaceuticals LimitedSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories LimitedSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Dr. Reddys Laboratories Inc.,SUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
NorthStar Rx LLCSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Proficient Rx LPSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Sportpharm LLCSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Sun Pharmaceutical Industries, Inc.SUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.SUMATRIPTAN SUCCINATE 4 mg/.5mLJul 15, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.SUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026
Xellia Pharmaceuticals USA LLCSUMATRIPTAN SUCCINATE 6 mg/.5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Sumatriptan Succinate — NDC 63323-0273-01," retrieved September 3, 2026, https://drugdashboards.com/drug/63323027301.

Free to cite with attribution — see how the data is put together.